Michael Halstead - 01 Mar 2025 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
04 Mar 2025, 18:01:07 UTC
Prior SEC filing
04 Feb 2025
Next SEC filing
10 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ John P. Condon, Attorney-in-fact
Filing notes and source

Key filing fact

Michael Halstead filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 04 Mar 2025.

Key facts

  • This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 04 Mar 2025, 18:01.

Change

  • Previous filing in this sequence was filed on 04 Feb 2025.
  • Current net transaction value: -$802,660.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITCI transaction

Common Stock

Options Exercise

Transaction value
Shares
+12,239
Change %
+230%
Price
Shares after
17,565
Date
01 Mar 2025
Ownership
Direct
Footnotes
F1
ITCI transaction

Common Stock

Tax liability

Transaction value
$802,660
Shares
-6,261
Change %
-36%
Price
$128.20
Shares after
11,304
Date
01 Mar 2025
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITCI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-12,239
Change %
-33%
Price
$0.000000
Shares after
24,478
Date
01 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
12,239
Exercise price
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units and does not represent a sale by the reporting person.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F4

On March 1, 2024, the reporting person was granted 36,717 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .